Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Drug Cards Daily

#19: memantine (Namenda) | Dementia Associated to Alzheimer’s Disease

22 Feb 2021

Description

Memantine is a NMDA antagonist that goes by the brand name Namenda. There are also titration packs available in the name brand. Memantine treats but does not cure confusion and dementia associated to Alzheimer’s disease. There are multiple dosage forms being a capsule, solution, and tablet. Special considerations are for patients with renal and hepatic impairment. Memantine does appear to have higher exposure in women than men. Memantine is purposed to work on the glutamate receptor blocking the receptor much like magnesium does under “normal” conditions. This drug has a long elimination half-life between 60-80 hours. The main side effects are weight gain, abdominal pain, constipation, diarrhea and vomiting. A serious side effect is Stevens Johnson Syndrome. Two main types of drugs that interact with Namenda are alkalinizing agents and carbonic anhydrase inhibitors. The drug can be taken with or without food and if a dose is missed it should not be doubled on the next dose. The missed dose should be skipped and resumed regularly.  Go to DrugCardsDaily.com for episode show notes which consist of the drug summary, quiz, and link to the drug card for FREE! Please SUBSCRIBE, FOLLOW, and RATE on Spotify, Apple Podcasts, or wherever your favorite place to listen to podcasts are. The main goal is to go over the Top 200 Drugs with the occasional drug of interest. Also, if you’d like to say hello, suggest a drug, or leave some feedback I’d really appreciate hearing from you! Leave a voice message at anchor.fm/drugcardsdaily or find me on twitter @drugcardsdaily

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.